Omada Health Inc

Omada Health Inc (OMDA) Stock Analysis

$17.630

-0.982 (-5.57%)At close

Loading chart…
High
18.970
Open
18.950
VWAP
18.03
Volume
808.04K
Mkt Cap
—
Low
17.480
Amount
14.57M
EV/EBITDA, TTM
41.18

Omada Health Inc. is a virtual-first healthcare provider that nurtures lifelong health. The Company has one operating segment, namely all virtual care program product offerings. The Company’s member-facing platform is designed to offer an integrated experience that encompasses the full range of direct interactions. It offers range of programs like Omada for Prevention & Weight Health, Omada for Diabetes, Omada for Hypertension, Omada for musculoskeletal (MSK), and Omada GLP-1 Care Tracks. Its Omada for Prevention & Weight Health programs focus on prediabetes and weight management, two critical elements of preventing diabetes and heart disease. Its Omada for Diabetes program is designed to help members with type 1 or type 2 diabetes achieve stable blood glucose levels and meet and reach their goals for reducing hemoglobin A1C. Its Omada for Hypertension is designed to help reduce members blood pressure and help them maintain healthy blood pressure.

AI analysis of Omada Health Inc (OMDA)

Hold

Omada Health Inc is currently trading at $17.63, which is below the analyst price target range of $25 to $35. However, the stock has a low RSI of 25.97, indicating it is oversold, but the forward P/E ratio is very high at 136.99, suggesting that the stock may be overvalued at this time. The recent insider selling by executives, including the CEO and President, raises some concerns about short-term confidence despite the company's long-term growth potential. Therefore, it may be prudent to hold off on buying until further clarity is provided in the upcoming Q3 earnings report on November 5, 2026.

Valuation Metrics

The current forward P/E ratio for Omada Health Inc (OMDA) is 136.99, compared to its 5-year average forward P/E of -105.51.

Forward P/E

Fair
5Y Average P/E
-105.51
Current P/E
136.99
Overvalued
707.05
Undervalued
-918.06

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
101.89
Current EV/EBITDA
41.18
Overvalued
477.83
Undervalued
-274.06

Forward P/S

Fair
5Y Average P/S
3.24
Current P/S
2.80
Overvalued
4.31
Undervalued
2.17

Whales holding OMDA

D

Divisadero Street Capital Management, LP

+ HoldingOMDA

-14.88%

3M Return

OMDA FAQ — answered by Alphio AI

Omada Health Inc. is a virtual-first healthcare provider that nurtures lifelong health. The Company has one operating segment, namely all virtual care program product offerings. The Company’s member-facing platform is designed to offer an integrated experience that encompasses the full range of direct interactions. It offers range of programs like Omada for Prevention & Weight Health, Omada for Diabetes, Omada for Hypertension, Omada for musculoskeletal (MSK), and Omada GLP-1 Care Tracks. Its Omada for Prevention & Weight Health programs focus on prediabetes and weight management, two critical elements of preventing diabetes and heart disease. Its Omada for Diabetes program is designed to help members with type 1 or type 2 diabetes achieve stable blood glucose levels and meet and reach their goals for reducing hemoglobin A1C. Its Omada for Hypertension is designed to help reduce members blood pressure and help them maintain healthy blood pressure. It operates in the Healthcare sector.

Omada Health Inc is currently trading at $17.63, which is below the analyst price target range of $25 to $35. However, the stock has a low RSI of 25.97, indicating it is oversold, but the forward P/E ratio is very high at 136.99, suggesting that the stock may be overvalued at this time. The recent insider selling by executives, including the CEO and President, raises some concerns about short-term confidence despite the company's long-term growth potential. Therefore, it may be prudent to hold off on buying until further clarity is provided in the upcoming Q3 earnings report on November 5, 2026.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading